ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1340

Anti-Aminoacyl-tRNA-Synthetase Antibodies Which Are Positive By ELISA but Negative By RNA-Immunoprecipitation Suggest Different Antigen Recognition and Clinical Relevance Different from Typical Anti-Synthetase Syndrome

Tsuneo Sasai1, Ran Nakashima2, Yuki Ishikawa3, Takuya Isayama4 and Tsuneyo Mimori2, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Japan, Kyoto, Japan, 2Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, 4Medical & Biological Laboratories CO.,LTD., Nagoya, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: myositis and synthetase syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-aminoacyl-tRNA-synthetase (ARS) antibodies are myositis specific autoantibodies and associated with common clinical characteristics called anti-synthetase syndrome (ASS). Recently anti-ARS detecting enzyme-linked immunosorbent assay (ELISA) in which mixture of 5 ARS antigens are coated have been established and utilized in daily practice (MESACUPTM MBL, Japan). However, we sometimes encounter patients who are positive for anti-ARS by ELISA but negative by RNA-immunoprecipitation (IP). We verified the authenticity and clinical relevance of these anti-ARSs with discrepant results between different detection systems.

Methods: We examined medical records of 1628 samples that were screened for anti-ARS by ELISA between 2014 and 2017. There were 78 patients (134 samples) who were positive for anti-ARS by ELISA, and among these patient, we further analyzed 61 patients by RNA-IP. We found 16 patients who were positive for anti-ARS by ELISA but negative by RNA-IP. We examined clinical characteristics of these 16 patient sera. Statistical analysis was performed by using Fisher’s exact test. Furthermore, 7 of 16 patients were examined by protein-IP and individual ELISA methods to verify the authenticity of the discrepant results. The individual ELISA was also confirmed whether the serum autoantibody was absorbed to the antigen.

Results: Compared to the previous report (Love LA. et al. Medicine (Baltimore), 1991), the frequency of all symptoms of ASS other than interstitial lung disease (ILD) were significantly lower in 16 discrepant cases (Table 1). The radiological patterns of ILD frequently showed nonspecific interstitial pneumonia and/or organizing pneumonia (11/16 cases). Most cases showed good response to initial glucocorticoid therapy, but 46% of them had recurrence. The results of protein-IP showed that 5 of 7 patient sera reacted with either Jo-1 or KS but 2 did not immunoprecipitated any ARS proteins. The individual ELISA and absorption study showed all these samples reacted with some of the ARS antigens, of which Jo-1 was the most frequently recognized (Table 2).

Conclusion: There are some anti-ARS antibodies which are detected by ELISA but not RNA-IP. These antibodies might inhibit RNAs binding to ARS proteins or recognize denatured ARS antigens. Patients with such atypical anti-ARS showed significant association with ILD but less with the other characteristics of ASS. Furthermore, the ILD with atypical anti-ARS showed similar clinical response and course with that of ASS. Further investigation is needed to clarify whether such patients have distinct form of ASS.


Disclosure: T. Sasai, None; R. Nakashima, Medical & Biological Laboratories Co., Ltd., 9; Y. Ishikawa, None; T. Isayama, Medical & Biological Laboratories Co.,LTD., Japan, 3; T. Mimori, Research grants, 2.

To cite this abstract in AMA style:

Sasai T, Nakashima R, Ishikawa Y, Isayama T, Mimori T. Anti-Aminoacyl-tRNA-Synthetase Antibodies Which Are Positive By ELISA but Negative By RNA-Immunoprecipitation Suggest Different Antigen Recognition and Clinical Relevance Different from Typical Anti-Synthetase Syndrome [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/anti-aminoacyl-trna-synthetase-antibodies-which-are-positive-by-elisa-but-negative-by-rna-immunoprecipitation-suggest-different-antigen-recognition-and-clinical-relevance-different-from-typical-anti-s/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-aminoacyl-trna-synthetase-antibodies-which-are-positive-by-elisa-but-negative-by-rna-immunoprecipitation-suggest-different-antigen-recognition-and-clinical-relevance-different-from-typical-anti-s/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology